A Phase 2 interventional study of CD5789 25 µg/g cream and CD5789 50 µg/g cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 24 sites in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2021-09-20.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 8th largest by enrollment, is the only one that started in 2012, is the only one in phase 2, and was the 1st registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2012.
This study's enrollment of 304 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 16th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2012, is one of 5 in phase 2, and was the 24th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Facial acne severity grade of the following:
A minimum of 30 non-inflammatory lesions and fulfills the criteria of one of the following strata:
Stratum 3: Participants of Japanese origin with at least 20 inflammatory lesions and up to four nodules on the face.
Exclusion Criteria:
Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
Drug: CD5789 25 µg/g cream
Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
Drug: CD5789 50 µg/g cream
Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
Drug: CD5789 100 µg/g cream
Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
Drug: Tazarotene 0.1% gel
Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
Drug: Vehicle cream
Drug page: Trifarotene
CD5789 25 µg/g cream applied once daily
Drug page: Trifarotene
CD5789 50 µg/g cream applied once daily
Drug page: Trifarotene
CD5789 100 µg/g cream applied once daily
Tazarotene 0.1% gel applied once daily
Vehicle cream applied once daily
Percentage of Participants With Success Rate 1 (SR1)
Success Rate 1 was defined as percentage of participants who achieved at least a two-point reduction in the Investigator Global Assessment (IGA) scale from baseline at week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by last observation carried forward (LOCF).
Time frame: From Baseline at Week 12
Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)
The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.
Time frame: Baseline, Week 12
Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)
The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.
Time frame: Baseline, Week 12
Percentage of Participants With Success Rate 2 (SR2)
Success Rate 2 (SR2) was defined as the percentage of participants rated "Clear" (Grade 0) or "Almost clear" (Grade 1) with at least a two-point reduction on the IGA scale from Baseline to Week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by LOCF.
Time frame: From Baseline to Week 12
Absolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)
The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF.
Time frame: Baseline, Week 12
Percentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)
The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF. Percent changes in lesion counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100.
Time frame: Baseline, Week 12
The study was conducted in United States. A total of 422 participants were screened between 20 June 2012 to 01 May 2013. Of which, 118 were screen failures. Screen failures were mainly due to inclusion criteria not met. A total of 304 participants were randomized in the study.
| Milestone | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | Vehicle Cream |
|---|---|---|---|---|---|
| Started | 61 | 61 | 60 | 61 | 61 |
| Completed | 56 | 53 | 50 | 53 | 49 |
| Not completed | 5 | 8 | 10 | 8 | 12 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 3 | 1 | 5 |
| Withdrew: Protocol violation | 0 | 5 | 2 | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 | 2 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 1 |
Success Rate 1 was defined as percentage of participants who achieved at least a two-point reduction in the Investigator Global Assessment (IGA) scale from baseline at week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by last observation carried forward (LOCF).
| percentage of participants | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | CD5789 Vehicle Cream |
|---|---|---|---|---|---|
| Percentage of Participants With Success Rate 1 (SR1) | 29.51 | 32.79 | 26.67 | 32.79 | 16.39 |
The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.
| lesion count | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | Vehicle Cream |
|---|---|---|---|---|---|
| Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF) | -53.61 ± 8.314 | -54.75 ± 8.261 | -54.99 ± 8.296 | -59.84 ± 8.301 | -46.87 ± 7.934 |
The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.
| percentage change | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | CD5789 Vehicle Cream |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF) | -47.59 ± 28.474 | -49.87 ± 24.731 | -50.72 ± 24.885 | -55.07 ± 26.295 | -40.48 ± 28.968 |
Success Rate 2 (SR2) was defined as the percentage of participants rated "Clear" (Grade 0) or "Almost clear" (Grade 1) with at least a two-point reduction on the IGA scale from Baseline to Week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by LOCF.
| percentage of participants | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | Vehicle Cream |
|---|---|---|---|---|---|
| Percentage of Participants With Success Rate 2 (SR2) | 13.11 | 14.75 | 16.67 | 21.31 | 8.20 |
The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF.
| lesion count | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | CD5789 Vehicle Cream |
|---|---|---|---|---|---|
| Inflammatory Lesions | -19.67 ± 14.874 | -21.11 ± 13.268 | -19.32 ± 11.566 | -21.03 ± 13.890 | -17.74 ± 15.073 |
| Non-inflammatory Lesions | -24.30 ± 21.633 | -18.69 ± 12.895 | -23.70 ± 18.390 | -28.26 ± 26.346 | -17.70 ± 17.745 |
The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF. Percent changes in lesion counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100.
| percentage change | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | CD5789 Vehicle Cream |
|---|---|---|---|---|---|
| Inflammatory lesion count | -49.16 ± 35.711 | -53.14 ± 30.187 | -51.93 ± 27.255 | -53.09 ± 29.484 | -41.70 ± 35.898 |
| Non-inflammatory lesion count | -46.34 ± 30.888 | -45.26 ± 29.331 | -49.57 ± 29.786 | -55.88 ± 28.913 | -38.20 ± 30.368 |
Collected over Adverse events (AEs) that occurred on or after the first dose of study medication through Week 14 Follow-up visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD5789 25 mcg/g Cream | 0/61 (0%) | 1/61 (1.6%) | 15/61 (24.6%) |
| CD5789 50 mcg/g Cream | 0/61 (0%) | 1/61 (1.6%) | 17/61 (27.9%) |
| CD5789 100 mcg/g Cream | 0/60 (0%) | 0/60 (0%) | 23/60 (38.3%) |
| Tazarotene 0.1% Gel | 0/61 (0%) | 0/61 (0%) | 24/61 (39.3%) |
| CD5789 Vehicle Cream | 0/61 (0%) | 1/61 (1.6%) | 18/61 (29.5%) |
| Event | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | CD5789 Vehicle Cream |
|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/61 | 0/61 | 0/60 | 0/61 | 1/61 |
| DepressionPsychiatric disorders | 0/61 | 1/61 | 0/60 | 0/61 | 0/61 |
| Event | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | CD5789 Vehicle Cream |
|---|---|---|---|---|---|
| Skin irritationSkin and subcutaneous tissue disorders | 0/61 | 0/61 | 6/60 | 5/61 | 0/61 |
| Upper respiratory tract infectionInfections and infestations | 2/61 | 3/61 | 4/60 | 1/61 | 6/61 |
| NasopharyngitisInfections and infestations | 4/61 | 1/61 | 5/60 | 5/61 | 1/61 |
| HeadacheNervous system disorders | 2/61 | 2/61 | 1/60 | 1/61 | 3/61 |
| InfluenzaInfections and infestations | 1/61 | 0/61 | 2/60 | 0/61 | 0/61 |
| PruritusSkin and subcutaneous tissue disorders | 0/61 | 0/61 | 2/60 | 1/61 | 0/61 |
| Skin burning sensationSkin and subcutaneous tissue disorders | 0/61 | 1/61 | 0/60 | 2/61 | 0/61 |
| Pityriasis albaSkin and subcutaneous tissue disorders | 0/61 | 0/61 | 0/60 | 2/61 | 0/61 |
| ExcoriationInjury, poisoning and procedural complications | 0/61 | 0/61 | 0/60 | 2/61 | 0/61 |
| Electrocardiogram abnormalInvestigations | 0/61 | 0/61 | 0/60 | 0/61 | 2/61 |
Analysis was performed on Intent to treat (ITT) population that included all participants who were randomized and to whom study drug was dispensed.
| Age, Continuous(years) | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | Vehicle Cream | Total |
|---|---|---|---|---|---|---|
| Mean | 18.1 ± 5.26 | 18.2 ± 4.76 | 18.3 ± 5.59 | 18.3 ± 4.83 | 18.3 ± 4.84 | 18.2 ± 5.03 |
| Sex: Female, Male(Participants) | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | Vehicle Cream | Total |
|---|---|---|---|---|---|---|
| Female | 15 | 8 | 12 | 17 | 13 | 65 |
| Male | 46 | 53 | 48 | 44 | 48 | 239 |
| Race (NIH/OMB)(Participants) | CD5789 25 mcg/g Cream | CD5789 50 mcg/g Cream | CD5789 100 mcg/g Cream | Tazarotene 0.1% Gel | Vehicle Cream | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 2 | 0 | 2 |
| Asian | 0 | 2 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 7 | 8 | 12 | 13 | 49 |
| White | 52 | 51 | 52 | 47 | 47 | 249 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 1 |
Ran from Jun 2012 to primary completion in Jul 2013, 13 months.
Results were first posted in Sep 2021, 8 years 1 month after primary completion. A results delay was requested in Jan 2014.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 13 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene